Page 177 - Read Online

Cheng et al. Advances in liver fibrosis

steatohepatitis (NASH): a randomized, phase 2 trial. Hepatology YJ, Lin SC, Chen CS, Lin TY, Wu WS. Hydrogen peroxide inducible
2015;63:1254A. clone-5 mediates reactive oxygen species signaling for hepatocellular
130. Berres ML, Koenen RR, Rueland A, Zaldivar MM, Heinrichs D, carcinoma progression. Oncotarget 2015;6:32526-44.
Sahin H, Schmitz P, Streetz KL, Berg T, Gassler N, Weiskirchen R, 142. Lei XF, Fu W, Kim-Kaneyama JR, Omoto T, Miyazaki T, Li B,
Proudfoot A, Weber C, Trautwein C, Wasmuth HE. Antagonism of Miyazaki A. Hic-5 deficiency attenuates the activation of hepatic
the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J stellate cells and liver fibrosis through upregulation of Smad7 in mice.
Clin Invest 2010;120:4129-40. J Hepatol 2016;64:110-7.
131. Mitchell C, Couton D, Couty JP, Anson M, Crain AM, Bizet V, 143. Schon HT, Bartneck M, Borkham-Kamphorst E, Nattermann J,
Renia L, Pol S, Mallet V, Gilgenkrantz H. Dual role of CCR2 in the Lammers T, Tacke F, Weiskirchen R. Pharmacological intervention in
constitution and the resolution of liver fibrosis in mice. Am J Pathol hepatic stellate cell activation and hepatic fibrosis. Front Pharmacol
2009;174:1766-75. 2016;7:33.
132. Sanyal A, Ratziu V, Harrison S, Abdelmalek MF, Aithal GP, 144. Tacke F, Trautwein C. Mechanisms of liver fibrosis resolution. J
Caballeria Jea. Cenicriviroc placebo for the treatment of non- Hepatol 2015;63:1038-9.
alcoholic steatohepatitis with liver fibrosis: Results from the Year 145. Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver
1 primary analysis of the Phase 2b CENTAUR study. Hepatology fibrosis. Compr Physiol 2013;3:1473-92.
2016;64:1118A. 146. Pines M, Spector I. Halofuginone -- the multifaceted molecule.
133. Traber PG, Chou H, Zomer E, Hong F, Klyosov A, Fiel MI, Friedman Molecules 2015;20:573-94.
SL. Regression of fibrosis and reversal of cirrhosis in rats by 147. Bruck R, Genina O, Aeed H, Alexiev R, Nagler A, Avni Y, Pines M.
galectin inhibitors in thioacetamide-induced liver disease. PLoS One Halofuginone to prevent and treat thioacetamide-induced liver fibrosis
2013;8:e75361. in rats. Hepatology 2001;33:379-86.
134. Galectin Therapeutics Announces Achievement of Key Milestones 148. Spira G, Mawasi N, Paizi M, Anbinder N, Genina O, Alexiev R,
Related to NASH-CX Clinical Trial. Available from: http://investor. Pines M. Halofuginone, a collagen type I inhibitor improves liver
galectintherapeutics.com/releasedetail.cfm?releaseid=1009928. [Last regeneration in cirrhotic rats. J Hepatol 2002;37:331-9.
accessed on 30 June 2017]. 149. Breitkopf K, Haas S, Wiercinska E, Singer MV, Dooley S. Anti-TGF-
135. Stenner J, Jazrawi R, Verma A, Ahmed H, Northfield T. Effect beta strategies for the treatment of chronic liver disease. Alcohol Clin
of UDCA on fibrosis markers in alcoholic liver disease. Clin Sci Exp Res 2005;29:S121-31.
2000;98:17p. 150. Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H. Blockade of type
136. Kim MY, Cho MY, Baik SK, Jeong PH, Suk KT, Jang YO, Yea CJ, beta transforming growth factor signaling prevents liver fibrosis and
Kim JW, Kim HS, Kwon SO, Yoo BS, Kim JY, Eom MS, Cha SH, dysfunction in the rat. Proc Natl Acad Sci U S A 1999;96:2345-9.
Chang SJ. Beneficial effects of candesartan, an angiotensin-blocking 151. Hayashi H, Sakai T. Biological significance of local tgf-beta activation
agent, on compensated alcoholic liver fibrosis - a randomized open- in liver diseases. Front Physiol 2012;3:12.
label controlled study. Liver Int 2012;32:977-87. 152. Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-
137. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes Ullrich JE. The activation sequence of thrombospondin-1 interacts
M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski with the latency-associated peptide to regulate activation of latent
M, Shapiro D. Efficacy and safety of the farnesoid X receptor agonist transforming growth factor-beta. J Biol Chem 1999;274:13586-93.
obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty 153. Kondou H, Mushiake S, Etani Y, Miyoshi Y, Michigami T, Ozono K.
liver disease. Gastroenterology 2013;145:574-82 e1. A blocking peptide for transforming growth factor-beta1 activation
138. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi prevents hepatic fibrosis in vivo. J Hepatol 2003;39:742-8.
P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, 154. Kim SJ, Ise H, Kim E, Goto M, Akaike T, Chung BH. Imaging and
Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, therapy of liver fibrosis using bioreducible polyethylenimine/siRNA
Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor complexes conjugated with N-acetylglucosamine as a targeting
KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, moiety. Biomaterials 2013;34:6504-14.
Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D, Group 155. Chatterjee A, Villarreal G, Jr., Rhee DJ. Matricellular proteins in the
PS. A placebo-controlled trial of obeticholic acid in primary biliary trabecular meshwork: review and update. J Ocul Pharmacol Ther
cholangitis. N Engl J Med 2016;375:631-43. 2014;30:447-63.
139. Zois CD, Baltayiannis GH, Karayiannis P, Tsianos EV. Systematic 156. Gressner OA, Gressner AM. Connective tissue growth factor:
review: hepatic fibrosis - regression with therapy. Aliment Pharmacol a fibrogenic master switch in fibrotic liver diseases. Liver Int
Ther 2008;28:1175-87. 2008;28:1065-79.
140. Huang Y, Deng X, Liang J. Modulation of hepatic stellate cells and 157. A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic
reversibility of hepatic fibrosis. Exp Cell Res 2017;352:420-6. Hepatitis B Infection. Available from: https://clinicaltrials.gov/ct2/
141. Wu JR, Hu CT, You RI, Pan SM, Cheng CC, Lee MC, Wu CC, Chang show/NCT01217632. [Last accessed on 30 June 2017].

Hepatoma Research ¦ Volume 3 ¦ August 08, 2017 169